Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
NCT06171789 is registered in ClinicalTrials.gov with Genmab as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
- Lead sponsor
- Genmab
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- January 3, 2024
- Completion date
- August 18, 2025
- Enrollment
- 33 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
endometrial cancer, gastroesophageal cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, urothelial carcinoma